These products were screened for their capacity to stimulate GLP-1 release from mouse STC-1 intestinal enteroendocrine cells 5,6,7
In the United States, the Centers for Disease Control and Prevention (CDC) reports that over 38.4 million individuals, approximately 11.6% of the population, are currently living with diabetes [2]
Endogenous GLP-1 is rapidly degraded primarily by dipeptidyl peptidase-4 (DPP-4), as well as neutral endopeptidase 24.11 (NEP 24.11) and renal clearance, resulting in a half-life of approximately 2 minutes
A recent CVOT meta-analysis showed that the magnitude of HbA1c reduction was correlated with retinopathy risk and was not associated with GLP-1RA treatment per se (50)
Regular follow-up to monitor glycemic control, weight, renal function, and tolerability is essential for optimizing therapeutic outcomes